- Home
- SITC vs ABUS Comparison
SITC vs ABUS Comparison
Compare SITC & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SITC
- ABUS
- Stock Information
- Founded
- SITC 1965
- ABUS 2005
- Country
- SITC United States
- ABUS United States
- Employees
- SITC N/A
- ABUS N/A
- Industry
- SITC Real Estate Investment Trusts
- ABUS Biotechnology: Pharmaceutical Preparations
- Sector
- SITC Real Estate
- ABUS Health Care
- Exchange
- SITC Nasdaq
- ABUS Nasdaq
- Market Cap
- SITC 603.6M
- ABUS 672.1M
- IPO Year
- SITC 1993
- ABUS N/A
- Fundamental
- Price
- SITC $11.92
- ABUS $3.36
- Analyst Decision
- SITC Hold
- ABUS Strong Buy
- Analyst Count
- SITC 8
- ABUS 4
- Target Price
- SITC $35.25
- ABUS $5.50
- AVG Volume (30 Days)
- SITC 558.3K
- ABUS 817.1K
- Earning Date
- SITC 05-07-2025
- ABUS 05-14-2025
- Dividend Yield
- SITC 4.40%
- ABUS N/A
- EPS Growth
- SITC 151.17
- ABUS N/A
- EPS
- SITC 10.32
- ABUS N/A
- Revenue
- SITC $227,525,000.00
- ABUS $6,403,000.00
- Revenue This Year
- SITC N/A
- ABUS $14.57
- Revenue Next Year
- SITC $17.57
- ABUS $15.84
- P/E Ratio
- SITC $1.15
- ABUS N/A
- Revenue Growth
- SITC N/A
- ABUS N/A
- 52 Week Low
- SITC $10.46
- ABUS $2.71
- 52 Week High
- SITC $18.15
- ABUS $4.73
- Technical
- Relative Strength Index (RSI)
- SITC 46.67
- ABUS 53.55
- Support Level
- SITC $11.55
- ABUS $3.04
- Resistance Level
- SITC $12.05
- ABUS $3.54
- Average True Range (ATR)
- SITC 0.25
- ABUS 0.14
- MACD
- SITC -0.02
- ABUS 0.02
- Stochastic Oscillator
- SITC 31.62
- ABUS 70.00
About SITC SITE Centers Corp.
SITE Centers Corp is a self-administered and self-managed REIT that operates as a fully integrated real estate company. The company is engaged in the business of owning, leasing, acquiring, redeveloping, developing and managing shopping centers.
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.